Last reviewed · How we verify

NCT03332524

Clinical Trial of the Safety and Efficacy of SP160412 in the Temporary Relief of Mild to Moderate Sunburn

Terminated Phase 2 Last updated 27 September 2019
What this trial tests

Phase 2 trial testing SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg in Sunburn in 80 participants. Terminated before completion.

Timeline
15 January 2018
Primary endpoint
25 September 2019
25 September 2019

Quick facts

Lead sponsorSephoris Pharmaceuticals LLC
PhasePhase 2
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designfactorial
Maskingquadruple
Primary purposetreatment
Enrollment80
Start date15 January 2018
Primary completion25 September 2019
Estimated completion25 September 2019
Sites1 location across Mauritius

Drugs / interventions tested

Conditions studied

Sponsor

Sephoris Pharmaceuticals LLC — full company profile →

Who can join

18 and older, any sex, with Sunburn. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A phase II multicenter, double-blinded clinical trial of the safety and efficacy of SP160412 in the temporary relief of mild to moderate, (i.e. first degree) sunburn

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sunburn

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03332524.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing